Evidence map›Paper›PMID 33668871›Full record

ArticleJournal of fungi (Basel, Switzerland)2021

Genetic and Phenotypic Characterization of in-Host Developed Azole-Resistant

Jochem B Buil, Jos Houbraken, Monique H Reijers, Jan Zoll, Maurizio Sanguinetti, Jacques F Meis, Paul E Verweij, Willem J G Melchers

Open access · goldAbstract read
In one paragraph

Article in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Epidemiological Characteristics of ClinicalJournal of fungi (Basel, Switzerland) · 2026
    Article
  2. Article
  3. DisseminatedFrontiers in medicine · 2026
    Article
  4. Contribution of the CYP51A Y119F Mutation to Azole Resistance inJournal of fungi (Basel, Switzerland) · 2025
    Article
  5. Article
  6. Review
  7. Refractory versus resistant invasive aspergillosis.The Journal of antimicrobial chemotherapy · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Jochem B BuilDepartment of Medical Microbiology, Radboud University Medical Center, 6525 GANijmegen, The Netherlands.
Jos HoubrakenWesterdijk Fungal Biodiversity Institute, 3584 CT Utrecht, The Netherlands.ORCID 0000-0003-4893-4438
Monique H ReijersCenter of Expertise in Mycology Radboudumc/CWZ, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0002-4401-5103
Jan ZollDepartment of Medical Microbiology, Radboud University Medical Center, 6525 GANijmegen, The Netherlands.ORCID 0000-0003-2155-7935
Maurizio SanguinettiDipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.ORCID 0000-0002-9780-7059
Jacques F MeisDepartment of Medical Microbiology, Radboud University Medical Center, 6525 GANijmegen, The Netherlands.ORCID 0000-0003-3253-6080
Paul E VerweijDepartment of Medical Microbiology, Radboud University Medical Center, 6525 GANijmegen, The Netherlands.ORCID 0000-0002-8600-9860
Willem J G MelchersDepartment of Medical Microbiology, Radboud University Medical Center, 6525 GANijmegen, The Netherlands.ORCID 0000-0002-5446-2230
Radboud University Nijmegen · NLUniversità Cattolica del Sacro Cuore · ITWesterdijk Fungal Biodiversity Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

acquired resistanceaspergillosisazole resistancechronic pulmonary aspergillosisCyp51AY119F

Identifiers

PMID33668871
PMCPMC7996152
OpenAlexW3131572350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.